ライフサイエンスコーパス: pharmacotherapy

1 nd could be the hallmark for future targeted pharmacotherapy.

2 cioeconomic inequity in access to this novel pharmacotherapy.

3 ders that are generally poorly controlled by pharmacotherapy.

4 ces and interventions compared with that for pharmacotherapy.

5 rders and thus has been a crucial target for pharmacotherapy.

6 ations between patients treated with AIT and pharmacotherapy.

7 timuli in a manner similar to antidepressant pharmacotherapy.

8 into patient-specific disease mechanism and pharmacotherapy.

9 of oculomotor control, often is resistant to pharmacotherapy.

10 is a cell-mediated process without effective pharmacotherapy.

11 ent modalities of surgery, radiotherapy, and pharmacotherapy.

12 d with a placebo control, as is standard for pharmacotherapy.

13 st in part, to underutilization of cessation pharmacotherapy.

14 (collectively termed youth) with OUD receive pharmacotherapy.

15 e intervention to improve early adherence to pharmacotherapy.

16 rth, and lactation, is a promising addiction pharmacotherapy.

17 subcutaneous immunotherapy (SCIT), or other pharmacotherapy.

18 selection and efficacy of smoking cessation pharmacotherapy.

19 beneficial adjunct agent in pain management pharmacotherapy.

20 esents an interesting, and novel, target for pharmacotherapy.

21 more targeted and individualized approach to pharmacotherapy.

22 subcutaneous immunotherapy (SCIT), or other pharmacotherapy.

23 son's disease patients subjected to standard pharmacotherapy.

24 on complication of glioblastoma and requires pharmacotherapy.

25 ion of the viability of CBD as a psychiatric pharmacotherapy.

26 iduals whose depression has not responded to pharmacotherapy.

27 alidated predictive biomarker of response to pharmacotherapy.

28 ve disorder who do not respond to first-line pharmacotherapy.

29 here has been a paucity of novel targets for pharmacotherapy.

30 severe HDM-induced AR despite treatment with pharmacotherapy.

31 ility for pain treatment and substance abuse pharmacotherapy.

32 lity to affective disorders, and response to pharmacotherapy.

33 receive net benefit from lifelong preventive pharmacotherapy.

34 ase pathophysiology, and may be a target for pharmacotherapy.

35 mes but do not guide selection of CBT versus pharmacotherapy.

36 th special reference to its integration with pharmacotherapy.

37 condition for which there is no FDA-approved pharmacotherapy.

38 ducts and to understand the effectiveness of pharmacotherapy.

39 1%) who received both behavioral therapy and pharmacotherapy.

40 ease the effectiveness of tobacco-dependence pharmacotherapy.

41 this system as a novel target for anxiolytic pharmacotherapy.

42 likely to respond favourably to dopaminergic pharmacotherapy.

43 rgency department, 317 (20%) were prescribed pharmacotherapy.

44 ial consequences for inflammation-resolution pharmacotherapy.

45 g the avoidance of allergen exposure and the pharmacotherapy.

46 where there is a critical need for improved pharmacotherapies.

47 nvestigated network activity and response to pharmacotherapies.

48 ation as candidate anti-cocaine use disorder pharmacotherapies.

49 e the mode of action of new lipid-regulating pharmacotherapies.

50 are no Food and Drug Administration-approved pharmacotherapies.

51 y U.S. Food and Drug Administration-approved pharmacotherapies.

52 significantly effective compared with other pharmacotherapies.

53 e primary outcome-was not prevented by these pharmacotherapies.

54 thus circumventing the efficacy of standard pharmacotherapies.

55 scape mechanisms from current antiangiogenic pharmacotherapies.

56 significantly effective compaired with other pharmacotherapies.

57 e targetable molecular mechanisms for future pharmacotherapies.

58 Food and Drug Administration (FDA)-approved pharmacotherapies.

59 mean predicted effect size for all but three pharmacotherapies.

60 ed to the conclusion that the combination of pharmacotherapies addressing single defects (e.g., trans

61 uld serve as potential molecular targets for pharmacotherapies aimed at reducing opioid use disorder.

62 Likewise, the question of whether pharmacotherapies aimed at the endocannabinoid system pr

63 ioral therapy alone, 159 (0.4%) who received pharmacotherapy alone, and 468 (1%) who received both be

64 a ratio higher than that of many neurologic pharmacotherapies already in clinical use.

65 evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patien

66 Despite the availability of effective pharmacotherapies and indications for some tailored phar

67 ntion and prevention strategies as it is for pharmacotherapies and pharmaceutical-oriented prevention

68 ecially for patients given shorter half-life pharmacotherapies and who boarded in the emergency depar

69 on, pulmonary arterial hypertension-targeted pharmacotherapy and balloon pulmonary angioplasty repres

70 Pharmacotherapy and bariatric surgery are promising inte

71 evidence for combined and extended cessation pharmacotherapy and behavioral strategies including prov

72 Pharmacotherapy and behavioral treatments for alcohol us

73 dalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidenc

74 Pharmacotherapy and device therapy are the primary metho

75 igh mortality despite advancements in modern pharmacotherapy and device therapy.

76 of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CB

77 Ustekinumab is a relatively new pharmacotherapy and in addition to this clinical case, w

78 pression severity, psychosocial functioning, pharmacotherapy and psychiatric history were noted.

79 Pharmacotherapy and psychosocial interventions are effec

80 us research on phenomenology, psychobiology, pharmacotherapy and psychotherapy has contributed to bet

81 the natural course of disease, to determine pharmacotherapy and the extent of surgery, and lately al

82 commercially insured youth with OUD received pharmacotherapy, and disparities based on sex, age, and

83 modification, increasing physical activity, pharmacotherapy, and surgery.

84 ed with the intensity of the common stepwise pharmacotherapy, and the concurrently included phenotypi

85 There were few trials of pharmacotherapy, and they had small sample sizes.

86 in addition to standard secondary prevention pharmacotherapy, and were followed up for a minimum of 1

87 At present, no approved pharmacotherapies are available for unclassifiable inter

88 No effective pharmacotherapies are available that reduce stimulant us

89 Although pharmacotherapies are in development, response rates app

90 se remains a public health concern for which pharmacotherapies are largely ineffective.

91 ion with inadequate response to conventional pharmacotherapy are discussed.

92 successfully with lifestyle intervention and pharmacotherapy are eligible for bariatric surgery, incl

93 reatment effect of allergy immunotherapy and pharmacotherapy are lacking.

94 d in guideline-directed use of neurohormonal pharmacotherapies as a standard of care in HF.

95 re administered chronically using a model of pharmacotherapy assessment that incorporates clinical as

96 Despite effective pharmacotherapy, asthma continues to impair quality of l

97 After adjustment for clustering by site, pharmacotherapy at discharge was associated with older a

98 In adjusted analyses, behavioral and/or pharmacotherapy-based AUD treatment was associated with

99 ry data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use di

100 of care for major depressive disorder (MDD) pharmacotherapy, but only approximately half of these pa

101 ding exposure therapy, are an alternative to pharmacotherapy, but the neurobiological mechanisms are

102 s and prevalence of US adults recommended BP pharmacotherapy by the 2017 ACC/AHA guideline based sole

103 is Perspective highlights the potential that pharmacotherapies capable of increasing inhibitory spina

104 py efficacy, the lack of an association with pharmacotherapy choice suggests there is scope to use NM

105 nd two conditional recommendations regarding pharmacotherapy choices.

106 ficient to compare efficacy within or across pharmacotherapy classes or versus behavioral therapy.

107 Pharmacotherapy, cognitive-behavioral therapy (CBT), and

108 lities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant

109 isen as a result of parallel developments in pharmacotherapy delivering the first effective treatment

110 rexin system is a potential novel target for pharmacotherapies designed to treat cocaine addiction.

111 A safe and effective fetal pharmacotherapy designed to modulate gene expression ide

112 n one pathway or the other using traditional pharmacotherapy (e.g., systemically administered drugs).

113 vances in intracoronary imaging, and adjunct pharmacotherapy-each of which is reviewed in other paper

114 Given its impact on pharmacotherapy efficacy, the lack of an association wit

115 ith vulnerability to affective disorders and pharmacotherapy efficacy.

116 tential target for development of drug abuse pharmacotherapies, especially for alcoholism, little is

117 ajor challenge and currently no FDA approved pharmacotherapies exist.

118 otherapies and indications for some tailored pharmacotherapies for African Americans (eg, heart failu

119 iterature supporting mGlu5 receptor drugs as pharmacotherapies for AUD.

120 s a clear need to identify and develop novel pharmacotherapies for cocaine addiction.

121 Current pharmacotherapies for depression exhibit slow onset, sid

122 tive effectiveness and long-term efficacy of pharmacotherapies for insomnia are not known.

123 Nonindicated and/or harmful pharmacotherapies for IPF were described as potential IP

124 derscores the urgency to develop alternative pharmacotherapies for managing pain.

125 ti-vascular endothelial growth factor (VEGF) pharmacotherapies for ME, including intravitreal bevaciz

126 et effects were numerically greater than all pharmacotherapies for PAR.

127 health crisis, the development of effective pharmacotherapies for the prevention and treatment of op

128 bstance use disorder (SUD), and there are no pharmacotherapies for the prevention of relapse.

129 oid receptor (KOR) antagonists are potential pharmacotherapies for the treatment of migraine and stre

130 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, in

131 facilitate the development of more efficient pharmacotherapy for acquired epilepsy.

132 could be one fruitful approach to innovative pharmacotherapy for bipolar disorder and related phenoty

133 combination of antigranulomatous therapy and pharmacotherapy for cardiac arrhythmias and/or heart fai

134 ts of cognitive behavioral therapy (CBT) and pharmacotherapy for childhood anxiety disorders.

135 There is a need for more effective pharmacotherapy for chronic pain, including pain in inhe

136 inically available anorectic and a candidate pharmacotherapy for cocaine addiction.

137 sulfonylurea drug glibenclamide, a potential pharmacotherapy for CS.

138 hibitors may provide a novel and fast-acting pharmacotherapy for depression.

139 randomized clinical trials comparing CBT and pharmacotherapy for depression.

140 apy is recommended as an adjunct to standard pharmacotherapy for individuals with symptoms and sensit

141 Effective pharmacotherapy for major depressive disorder remains a

142 le there has been progress in developing new pharmacotherapy for mania, developing effective treatmen

143 Pharmacotherapy for meningiomas has remained largely exp

144 ) procedure in rats to examine oxytocin as a pharmacotherapy for methamphetamine (meth) addiction.

145 Pharmacotherapy for obesity management can fill an impor

146 There is no effective pharmacotherapy for OSA.

147 nical settings could contribute to precision pharmacotherapy for pain and addiction.

148 ugh levodopa remains the most effective oral pharmacotherapy for Parkinson disease (PD), its use is o

149 ing regarding when, why, and how to initiate pharmacotherapy for Parkinson's disease.

150 The selection of pharmacotherapy for patients with allergic rhinitis (AR)

151 potential for new and effective tailor-made pharmacotherapy for patients with Cushing's syndrome.

152 effects, suggesting its potential for use in pharmacotherapy for post-traumatic stress disorder.

153 s with mild to moderate COPD, the benefit of pharmacotherapy for reducing exacerbations was modest.

154 and adverse effects of single or combination pharmacotherapy for seasonal allergic rhinitis.

155 gement strategy that includes counseling and pharmacotherapy for smoking cessation, pulmonary rehabil

156 are distinct ocular advantages to anti-VEGF pharmacotherapy for some cases (such as eyes with zone I

157 advances over the past decade in combination pharmacotherapy for the management of obesity and type 2

158 within 6 months after intravitreal anti-VEGF pharmacotherapy for the treatment of DME in routine clin

159 rehensive assessment of GDF15 as a potential pharmacotherapy for the treatment of obesity.

160 No effective pharmacotherapy for these core deficits exists.

161 Varenicline, a pharmacotherapy for tobacco addiction, reduces alcohol c

162 eCBs in the proextinction effects of a major pharmacotherapy for trauma- and stressor-related disorde

163 s clinical trials investigating intravitreal pharmacotherapy for treatment of CRVO-associated macular

164 Epinephrine is the first-line pharmacotherapy for uniphasic and/or biphasic anaphylaxi

165 inform the growing use of GABA(B)R-selective pharmacotherapy for various motivational disorders, incl

166 omplete biochemical remission (P = 0.07) and pharmacotherapy-free interval (P = 0.06).

167 e as predictors of biochemical remission and pharmacotherapy-free interval in patients with metastati

168 alyzed as marker of biochemical response and pharmacotherapy-free interval.

169 ment with lithium continues as the benchmark pharmacotherapy, functioning as a potent mood stabilizer

170 th other therapies (differential g=0.06) and pharmacotherapy (g=-0.13).

171 tics (nicotine replacement therapy vs. other pharmacotherapy; group vs. one-to-one behavioural suppor

172 f three 12-week open-label smoking cessation pharmacotherapy groups: (1) nicotine patch only (n = 241

173 Our results demonstrate that pharmacotherapy guided by genomic analysis, molecular mo

174 The FDA documents reported that most pharmacotherapies had risks for cognitive and behavioral

175 ti-vascular endothelial growth factor (VEGF) pharmacotherapy has become standard of care for the mana

176 on lung-protective ventilation; no specific pharmacotherapies have been identified.

177 Efforts to develop potential pharmacotherapies have led to the identification of a pr

178 tments including diet, exercise, surgery and pharmacotherapies have so far failed to reverse obesity

179 s) represent the gold standard of anxiolytic pharmacotherapy; however, their clinical benefit is limi

180 Pharmacotherapy, implantable cardioverter-defibrillators

181 o 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up.

182 Clinical guidelines advise against pharmacotherapy in bronchiolitis.

183 -PV neurons may represent a novel target for pharmacotherapy in disorders such as schizophrenia which

184 nd SLIT were significantly better than other pharmacotherapy in most assessment.

185 quential model, which consists of the use of pharmacotherapy in the acute phase and of psychotherapy

186 ng of the risk of serious infection from IBD pharmacotherapy in the adult population.

187 apy after successful response to acute-phase pharmacotherapy in the treatment of adults with major de

188 s fall within the broad concept of "rational pharmacotherapy," in that they attempt to directly targe

189 Their pharmacotherapy included oral levodopa plus benserazide

190 inflammatory agents, and first-line systemic pharmacotherapy includes tricyclic antidepressants and a

191 of opioid substance use disorder, and while pharmacotherapies including opioid agonists and antagoni

192 children; care of women in pregnancy; use of pharmacotherapies, including ezetimibe and PCSK9 inhibit

193 patients' preference for psychotherapy over pharmacotherapy, increasing patient access to CBT may be

194 oting early diagnosis of APRT deficiency and pharmacotherapy initiation before kidney transplantation

195 guideline was created that addresses several pharmacotherapy-initiation questions that routinely conf

196 Injection of pharmacotherapy into the suprachoroidal space, between t

197 The sequential integration of CBT and pharmacotherapy is a viable strategy for preventing rela

198 In other metabolic diseases, pharmacotherapy is an accepted adjunct to lifestyle.

199 algorithm guiding therapeutic decisions and pharmacotherapy is presented.

200 Intervening early with pharmacotherapy is recommended by major professional org

201 Due to the emergence of new possibilities of pharmacotherapy, it has become crucial to identify the g

202 of CFTR mutants and their susceptibility to pharmacotherapy, it has been recognized that mutations m

203 heral afferent sensory neurons by anticancer pharmacotherapy, leading to debilitating neuropathic pai

204 icolimbic regions, suggesting that available pharmacotherapies may alleviate deficits in the same cir

205 Thus, we reasoned that 5-HT(2A)R pharmacotherapies may ameliorate the stress-induced dysr

206 Pharmacotherapy may produce clinician-rated superior imp

207 transplant, in combination with the current pharmacotherapy, may be a novel strategy for hypertensio

208 ve and Negative Syndrome Scale data from the Pharmacotherapy Monitoring and Outcome Survey cohort (15

209 with metacognitive rehabilitation (MAAT) and pharmacotherapy (MPH) can improve aspects of attention,

210 The pharmacotherapy of chronic HP consists of immunosuppress

211 t BK channels are promising drug targets for pharmacotherapy of metabolic disorders and obesity.

212 CSF1 and DAP12 are potential targets for the pharmacotherapy of neuropathic pain.

213 kinetics/dynamics, and cholesterol-targeted pharmacotherapy of PAP in vitro and in vivo.

214 ility of translating pioglitazone as a novel pharmacotherapy of PAP.

215 earch that provides an evidence base for the pharmacotherapy of people with mental disorders is neede

216 All patients participated in the Study of Pharmacotherapy of Psychotic Depression II randomized co

217 In these patients, use of pharmacotherapy on the basis of the predominant symptom

218 In the context of contemporary pharmacotherapy, optimal antiplatelet management with pe

219 All participants received protocolized pharmacotherapy optimized by flexible dosing, psychoeduc

220 In an effort to expand the limited pharmacotherapy options for opioid use disorders, a hero

221 patients with obesity may also benefit from pharmacotherapy or bariatric surgery.

222 eline factors associated with AUD treatment (pharmacotherapy or behavioral therapy) and clinical outc

223 or separation anxiety and who received CBT, pharmacotherapy, or the combination.

224 despite social distancing restrictions, and pharmacotherapy, particularly for those with diabetes.

225 ti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a central role in the management o

226 harmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus continuation ECT.

227 Pharmacotherapies potentiating alpha7 nAChR signaling ha

228 The primary outcome was pharmacotherapy prescription at discharge from the emerg

229 Pharmacotherapy provision based on Nicotine Metabolite R

230 Seven pharmacotherapy randomized controlled trials (n=2809) an

231 genotype results along with genotype-guided pharmacotherapy recommendations using a rapid turnaround

232 otype information along with genotype-guided pharmacotherapy recommendations.

233 lifestyle intervention may be candidates for pharmacotherapy, recommended as an adjunct.

234 ion, goal-directed haemodynamically targeted pharmacotherapy remains the cornerstone of treatment for

235 nergistically rescued common (DeltaF508) and pharmacotherapy-resistant (N1303K) CF mutations when com

236 In addition, careful consideration of when pharmacotherapy should be started and choice of medicati

237 cell populations in vivo using growth factor pharmacotherapy show that cf-mRNA reflects dynamic funct

238 y from cognitive-behavioral therapy (CBT) or pharmacotherapy, some experience divergent outcomes.

239 ors appear efficacious, but the few existing pharmacotherapy studies were short term (</=4 months), a

240 sion making is affected by abstinence and by pharmacotherapies such as nicotine replacement therapy a

241 luable advancements in comparison to current pharmacotherapy such as small molecule drugs or antibodi

242 cular disease to guide the use of preventive pharmacotherapies, such as aspirin, lipid-lowering media

243 apy (often cognitive behavioral therapy) and pharmacotherapy, such as selective serotonin reuptake in

244 Traditional pharmacotherapy suffers from multiple drawbacks that ham

245 Thus, both T cell immunity and trypanocidal pharmacotherapy suppress to very low levels, but do not

246 er the past few years, management (including pharmacotherapy, surgery and biologics) has experienced

247 the nature of fibroids and their diagnosis, pharmacotherapy, surgical treatment, and nonsurgical int

248 ches and molecular targets to develop future pharmacotherapy targeted to the vagus nerve for the trea

249 Despite proven efficacy of pharmacotherapies targeting primarily global neurohormon

250 se findings add to the growing evidence that pharmacotherapies targeting the KOR have the potential t

251 Thus, pharmacotherapy targeting NMDA receptors may inadvertent

252 tion (odds ratio=1.67) were more frequent in pharmacotherapy than in CBT.

253 Development of pharmacotherapies that promote remyelination is a high p

254 arted therapies before pollen dispersal, 254 pharmacotherapy that started therapies after pollen disp

255 arted therapies before pollen dispersal, 221 pharmacotherapy that started therapies after pollen disp

256 third treated year with 38 SCIT, 364 primary pharmacotherapy that started therapies before pollen dis

257 2016, of 133 SLIT with 46 SCIT, 351 primary pharmacotherapy that started therapies before pollen dis

258 balance control and is a target for obesity pharmacotherapies, the receptor-population-mediating eff

259 ree AMI care including guideline-recommended pharmacotherapy, timely provision of medical and reperfu

260 valuate the impact of optimal cardiovascular pharmacotherapies to prevent POAF and to decrease the ri

261 The ability of pharmacotherapies to prevent relapse and maintain effica

262 are no Food and Drug Administration-approved pharmacotherapies to prevent relapse to the use of stimu

263 g such mechanisms will inform development of pharmacotherapies to reduce carcinogenesis.

264 as a potential target for the development of pharmacotherapies to treat alcohol use disorders, yet li

265 Still, pharmacotherapies to treat AUD are scarce.

266 nalysis, we sought to identify predictors of pharmacotherapy to further the clinical implementation o

267 senescence and CKD may expand the arsenal of pharmacotherapy to include the judicious use of senother

268 Treatment options are broad ranging, from pharmacotherapy to invasive neuromodulation and experime

269 Such techniques may allow tailoring of pharmacotherapy to potentiate thrombus instability, thro

270 Pharmacotherapy to rapidly relieve suicidal ideation in

271 mation for a more individualized approach to pharmacotherapy, to maximize the benefit versus risk rat

272 dherence, which includes failure to initiate pharmacotherapy, to take medications as often as prescri

273 macological effects and aid a more efficient pharmacotherapy towards neuropsychological conditions.

274 ng AUD did not receive behavioral therapy or pharmacotherapy treatment for AUD over a 6-month follow-

275 allowed rescue medication use, whereas most pharmacotherapy trials did not.

276 randomized, placebo-controlled adjunct oral pharmacotherapy trials in this patient population.

277 Reasons for treatment discontinuation in pharmacotherapy trials were infrequently reported (35%),

278 In adjusted analysis, pharmacotherapy type was not associated with NMR status,

279 Japan account for the majority of biological pharmacotherapy use worldwide.

280 vity are the primary treatments for GDM, but pharmacotherapy, usually insulin, is used when normoglyc

281 d remitted were randomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacoth

282 Anti-VEGF pharmacotherapy was not associated with an increased haz

283 Discharge pharmacotherapy was not associated with revisits (p=0.55

284 ial, the use of allergic rhinoconjunctivitis pharmacotherapy was significantly less (27% relative dif

285 Access to pharmacotherapy was via primary care after discussion wi

286 Risks associated with aspects of pharmacotherapy were also examined in the full cohort.

287 UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (od

288 Therefore, effective combination pharmacotherapies, which have included non-steroidal ant

289 red as a potential moderator of efficacy for pharmacotherapies with neuroimmune effects, such as IBUD

290 n tension, cell density, growth factors, and pharmacotherapy with an antineoplastic agent (Erlotinib)

291 level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and s

292 oral and psychological symptoms of dementia, pharmacotherapy with antidementia drugs, and use of pote

293 Targeted pharmacotherapy with Avpr1b agonists or deep brain stimu

294 n components of existing care models include pharmacotherapy with buprenorphine or naltrexone, provid

295 subjects then received 8 wk of standardized pharmacotherapy with escitalopram.

296 The usual medical treatment of dystonia is pharmacotherapy with nonselective antagonists of muscari

297 First-line pharmacotherapy with propranolol has reduced but not abo

298 were delivered at a group level, or provided pharmacotherapy with standard behavioural support compar

299 -naive and had not received any intravitreal pharmacotherapy within 6 months of UWFA.

300 on (28.4%), untreated condition (19.4%), and pharmacotherapy without indication (11.9%).